Trials / Completed
CompletedNCT01698801
A Phase 2 Study of Lenalidomide to Evaluate the Efficacy in Japanese Patients With Newly Diagnosed Multiple Myeloma
A Phase 2, Multicenter, Open-label, Single Arm Study of Lenalidomide (CC-5013) in Combination With Low-dose Dexamethasone in Japanese Patients With Previously Untreated Multiple Myeloma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 26 (actual)
- Sponsor
- Celgene · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
To determine the efficacy of lenalidomide in combination with low-dose dexamethasone in Japanese subjects with previously untreated multiple myeloma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lenalidomide | 25 mg oral lenalidomide once daily on Days 1-21 of each 28-day cycle |
| DRUG | dexamethasone | 40 mg oral dexamethasone once daily on Days 1, 8, 15 and 22 of each 28-day cycle |
Timeline
- Start date
- 2012-10-01
- Primary completion
- 2013-11-26
- Completion
- 2018-06-26
- First posted
- 2012-10-03
- Last updated
- 2018-11-08
- Results posted
- 2014-12-03
Locations
24 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT01698801. Inclusion in this directory is not an endorsement.